Oncolix Appoints Two Members to Its Board of Directors

Board Members bring Clinical and Manufacturing Expertise to Clinical-Stage Biopharmaceutical Company

Independent Board Member Appointment Step toward NASDAQ Listing Objective

HOUSTON, Oct. 04, 2017 -- Oncolix, Inc. (OTC PINK:AEPP) (the “Company”), a biotechnology company focused on gynecological cancers, announced on October 4, 2017, the Board of Directors voted to increase the number of directors to three from the current two and elected Jerry R. Youkey, M.D., and Dale Zajicek to serve on the Company’s Board of Directors. Mr. Zajicek is the first independent board member of the company.

Dr. Youkey and Mr. Zajicek have served as Directors of the Company’s wholly owned subsidiary, Oncolix, Inc., (a Delaware corporation) since 2007. In connection with such action, J. Donald Payne resigned as a director of the Company but continues to serve as its secretary. Michael T. Redman, chief executive officer of Oncolix, continues to serve as the Company’s third director. The term of all directors continues until their reelection or replacement by action of the stockholders of the Company.

“Following the completion of the merger in August 2017, we have been focused on building an innovative biopharmaceutical company with the objective of developing and launching our lead candidate, Prolanta™, to treat ovarian and other cancers,” said Michael T. Redman, president and CEO of Oncolix. “Part of that process is to build the public company infrastructure that will first fulfill the OTC-QB requirement to have at least two independent directors and, ultimately, to qualify for a NASDAQ listing. The appointment of Mr. Zajicek as an independent director assists with that objective. In addition, both appointees have already made valuable contributions and will be instrumental in adding additional world-class board members. Oncolix will soon be adding an independent fourth director, which will also fulfill the OTC-QB requirement.”

Jerry R. Youkey, M.D.

Jerry R. Youkey, M.D., joined Greenville Health System (GHS) in 1998, and currently serves as GHS Executive Vice President and Chief Academic Officer, reporting to the CEO. GHS is an eight-campus integrated delivery system with 1,756 beds, employing approximately 14,000 employees and 1,000 medical doctors.  Since 2011, Dr. Youkey has additionally served as Founding Dean of University of South Carolina School of Medicine Greenville and in 2015, was appointed University of South Carolina Associate provost for Health Sciences Greenville.

Dr. Youkey served a rotating internship and general surgery residency at William Beaumont Army Medical Center, El Paso, TX, and a fellowship in peripheral vascular surgery at Walter Reed Army Medical Center, Washington D.C. He also served in the U.S. Army and was honorably discharged in August 1984, after attaining the rank of Colonel, Medical Corps. Dr. Youkey served as Chief, Department of Surgery and Director, Peripheral Vascular Surgery Fellowship Program at Geisinger Medical Center, Danville, PA, prior to coming to Greenville. He is certified by the American Board of Surgery in general vascular surgery.

He is widely published in his specialty field of general vascular surgery, having authored books, abstracts and journal articles. He holds the academic appointment of Professor and Associate Dean at the University of South Carolina, Columbia, SC. He received his B.A. from Stanford University, Palo Alto, CA, his medical degree from the Medical College of Wisconsin, Milwaukee, WI and is a member of numerous professional societies and organizations.

Dale Zajicek

Mr. Zajicek has over 37 years of experience in the pharmaceutical and biotechnology industry. In 2015, he retired as President of BioVectra, Inc., a company he joined in 1995. Following his promotion to Chief Operating Officer of BioVectra in 2005, he was responsible for growth of the firm’s contract manufacturing and drug development efforts, with the firm filing numerous Drug Master Files (DMF) and Investigational New Drug applications (IND) and supported the New Drug Applications for numerous clients. Mr. Zajicek successfully led BioVectra in the development of generic docetaxel, and obtained “first to file” status for this oncology drug. BioVectra partnered the product with Sandoz for the U.S. market, and other marketing firms for markets in Canada, Europe, Middle East, North Africa, and South America. Under Mr. Zajicek’s leadership, BioVectra has developed capabilities in microbial fermentation for protein-based and small molecule drugs, as well as combining biotech processing with synthetic capabilities to perform unique chemistries and conjugations of large to small molecules. 

Prior to joining BioVectra, Mr. Zajicek held positions in manufacturing operations, engineering, research and product development, and business development at G.D. Searle and The NutraSweet Company.  Mr. Zajicek holds a B.S. in Chemical Engineering from Illinois Institute of Technology and a B.S. in Business Administration from Elmhurst College.

Corporate contact:
Michael Redman
P: 281-402-3167
E: [email protected]

Investor contact:
The Ruth Group
Robert Flamm
P: 646-536-7017
E: [email protected]